BIAFW bioAffinity Technologies, Inc.

NEUTRAL Impact: 2/10 8-K
Horizon weeks Filed Jun 2, 2026 Processed 4d 10h ago SEC 0001493152-26-026773
8-K context-dependent: Items 8.01
Latest settled — T+1d
BIAFW ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY +0.69% · entry $0.2950 → $0.2950
Next anchor: T+5d in 3d
Currently $0.2950 · -0.00% from $0.2950 entry
Entry anchored
Jun 2, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.69%
$0.2950
settled 3d ago
T+5d
call — · α —
in 3d
T+20d
call — · α —
in 25d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

bioAffinity Technologies announced via an 8-K that the Society for Advanced Bronchoscopy will host a webinar on June 16, 2026, featuring a multidisciplinary physician panel discussing the real-world use of the company's CyPath Lung test for early-stage lung cancer detection and management. This is a routine educational and marketing event with no financial data, guidance, or material business developments disclosed.

Actionable Insight

This filing is a routine marketing/promotional event with no material financial data. Traders should monitor future 10-Q filings for any revenue traction or reimbursement updates for CyPath Lung, but no immediate trading action is warranted.

Key Facts

  • Webinar titled 'Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath Lung Testing' scheduled for June 16, 2026 at 7 p.m. ET.
  • Panel includes an interventional pulmonologist, medical oncologist, and thoracic surgeon.
  • CyPath Lung is a noninvasive test using flow cytometry and AI, marketed as a Laboratory Developed Test (LDT).
  • No financial figures, revenue data, guidance, or material agreements were disclosed in the filing.

Financial Impact

No financial impact disclosed; the filing is a routine educational event announcement.

Risk Factors

  • CyPath Lung is marketed as an LDT and faces regulatory uncertainty regarding FDA oversight of LDTs.
  • No disclosed revenue or adoption metrics — commercial traction remains unquantified.
  • Company has a micro-cap market cap ($1M) with limited liquidity and high volatility risk.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-026773
Exhibit: ex99-1.htm0001493152-26-026773
Document: 0001493152-26-026773-index-headers.html0001493152-26-026773
Document: 0001493152-26-026773-index.html0001493152-26-026773
Document: 0001493152-26-026773.txt0001493152-26-026773
7 reports for BIAFW
Performance horizon
Filters
Rows
Reports for BIAFW — sortable, filterable
Type Now
Jun 2, 2026
4d ago
8-K
NEUTRAL ★ 2/10
$0.2950 $0.2950· 0.00%▲ +0.69%$0.2950 (−0.00%)
May 27, 2026
10d ago
8-K
NEUTRAL ★ 4/10
$0.2950 $0.2000▼ −32.20%▼ −32.75%$0.2950 (−0.00%)
May 13, 2026
24d ago
EFFECT
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▼ −0.78%$0.2950 (−0.00%)
May 12, 2026
25d ago
8-K
NEUTRAL ★ 4/10
$0.2950 $0.2950· 0.00%▼ −0.58%$0.2950 (−0.00%)
May 8, 2026
29d ago
8-K
MIXED ★ 5/10
$0.2950 $0.2950· 0.00%▼ −0.23%$0.2950 (−0.00%)
Apr 14, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▼ −0.77%$0.2950 (−0.00%)
Apr 7, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▼ −2.54%$0.2950 (−0.00%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (14h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access